The BRAINTEASER Community of Practice Second webinar Advances in digital technology are helping us to predict the onset of a disease, how it will progress, or which is the best treatment option for a particular person. In other words, technology
InSilicoTrials partners with Axoltis Pharma to leverage advanced modeling technology, generating predictive analyses of disease progression in virtual subjects based on the baseline characteristics of actual enrolled patients. This collaboration will enhance the development of Axoltis’s NX210c by accelerating the
InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the battle against age-related conditions, by improving its safety profile and reducing development costs. BALTIMORE, March 07, 2024 (GLOBE
The realm of healthcare and life sciences is undergoing a transformative shift, fueled by the advent and integration of data-driven technologies. At the forefront of this revolution is the burgeoning use of synthetic data, a groundbreaking development poised to redefine
In the Webinar: Women in Multiple Sclerosis, hosted by the Community of Practice of the BRAINTEASER project, we focused on the role of hormones on the onset and progression of the disease and delved deeply into several aspects of pregnancy.
InSilicoTrials is thrilled to announce the publication of “𝙏𝙤𝙬𝙖𝙧𝙙 𝙂𝙤𝙤d 𝙎𝙞𝙢𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙋𝙧𝙖𝙘𝙩𝙞𝙘𝙚 – Best practices for the use of computational modelling & simulation in the regulatory process of biomedical products ” a crucial document guiding the use of simulation data
At the Brain Innovation Days held in Brussels on October 26-27, 2023, organised by the European Brain Council, representatives from the BRAINTEASER project and from other pertinent initiatives gathered for a roundtable discussion. The focus was on promoting collaboration among various EU
iDPP@CLEF [1] is an open evaluation challenge to assess the performance of Artificial Intelligence (AI) algorithms to predict the progression of Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). iDPP stands for Intelligent Disease Progression Prediction and it is a series of events, organised by the BRAINTEASER project, co-located with the Conference
Axoltis Pharma is at the forefront of developing treatments for neurodegenerative diseases, with their phase 1b clinical trial of NX210c marking a notable achievement in the field. This peptide drug candidate has shown promising results following a successful phase 1a
The life sciences sector is beginning to experience the transformative effects of AI, with numerous applications offering clinical, operational, and medical advantages. Unlike other industries, life sciences face the unique challenge of safeguarding patient safety and privacy. This has led
Mamede de Carvalho, a renowned neurologist and the head of the Amyotrophic Lateral Sclerosis (ALS) Clinic at Centro Hospitalar Universitário Lisboa Norte (CHULN), situated at the prestigious Hospital de Santa Maria, recently unveiled the exciting BRAINTEASER project during an exclusive
Welcome back to InSilicoTrials’ Talks! We’re excited to launch our IST Customer Testimonials’ initiative, a series dedicated to hearing directly from our clients. Today, we feature Yann Godfrin, CEO of Axoltis Pharma, who joined us for an insightful in silico